Lower expression of tumor microRNA‐26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment

Jones, Keaton R.; Nabinger, Sarah C.; Lee, Sangbin; Sahu, Smiti Snigdha; Althouse, Sandra K.; Saxena, Romil; Johnson, Matthew S.; Chalasani, Naga; Gawrieh, Samer; Kota, Janaiah

doi:10.1002/jso.25156

Cited by 7 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBV might influence miR expression and induce inflammatory cytokine production [91]. Previous reports indicated that some hepatic miRs are involved in the pathogenesis of HBV-associated HCC [92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142], with certain serum miRs involved in HBV-associated HCC also potentially useful as biomarkers (Table 2).…”

Section: Molecular Mechanisms Of Hbv-associated Hccmentioning

confidence: 99%

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

Kanda

Goto

Hirotsu

et al. 2019

IJMS

224

145

View full text Add to dashboard Cite

Almost all patients with hepatocellular carcinoma (HCC), a major type of primary liver cancer, also have liver cirrhosis, the severity of which hampers effective treatment for HCC despite recent progress in the efficacy of anticancer drugs for advanced stages of HCC. Here, we review recent knowledge concerning the molecular mechanisms of liver cirrhosis and its progression to HCC from genetic and epigenomic points of view. Because ~70% of patients with HCC have hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection, we focused on HBV- and HCV-associated HCC. The literature suggests that genetic and epigenetic factors, such as microRNAs, play a role in liver cirrhosis and its progression to HCC, and that HBV- and HCV-encoded proteins appear to be involved in hepatocarcinogenesis. Further studies are needed to elucidate the mechanisms, including immune checkpoints and molecular targets of kinase inhibitors, associated with liver cirrhosis and its progression to HCC.

show abstract

Section: Molecular Mechanisms Of Hbv-associated Hccmentioning

confidence: 99%

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

Kanda

Goto

Hirotsu

et al. 2019

IJMS

224

145

View full text Add to dashboard Cite

show abstract

“…Furthermore, low expression of miR-26a correlated with a poor prognosis of HCC patients [144,176]. This finding was also confirmed in patients with HBV-induced HCC [177]. MiR-26a was also associated with resistance to the chemotherapeutic drug doxorubicin [173].…”

Section: Microrna-26amentioning

confidence: 58%

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Linck-Paulus

Hellerbrand

Bosserhoff

et al. 2020

Cells

View full text Add to dashboard Cite

In this review, we summarize the current knowledge on miRNAs as therapeutic targets in two cancer types that were frequently described to be driven by miRNAs—melanoma and hepatocellular carcinoma (HCC). By focusing on common microRNAs and associated pathways in these—at first sight—dissimilar cancer types, we aim at revealing similar molecular mechanisms that are evolved in microRNA-biology to drive cancer progression. Thereby, we also want to outlay potential novel therapeutic strategies. After providing a brief introduction to general miRNA biology and basic information about HCC and melanoma, this review depicts prominent examples of potent oncomiRs and tumor-suppressor miRNAs, which have been proven to drive diverse cancer types including melanoma and HCC. To develop and apply miRNA-based therapeutics for cancer treatment in the future, it is essential to understand how miRNA dysregulation evolves during malignant transformation. Therefore, we highlight important aspects such as genetic alterations, miRNA editing and transcriptional regulation based on concrete examples. Furthermore, we expand our illustration by focusing on miRNA-associated proteins as well as other regulators of miRNAs which could also provide therapeutic targets. Finally, design and delivery strategies of miRNA-associated therapeutic agents as well as potential drawbacks are discussed to address the question of how miRNAs might contribute to cancer therapy in the future.

show abstract

“…Tumour progression was evaluated in three studies [16,18,19] . Recurrence rate and prognosis were the main objectives in four studies [17,[20][21][22] , respectively eight studies [23][24][25][26][27][28][29][30] . Lee et al studied the correlation between AFP values and the resection margins in patients with minor or major liver resections for HCC [31] .…”

Section: Resultsmentioning

confidence: 99%

“…The RNAs were used as prognostic markers for recurrence rate and mortality, overall survival and tumor progression. Jones et al and von Felden et al investigated the role of miRNAs regarding the recurrence of hepatocellular carcinoma after curative liver resections [20,21] . Jones et al included only a North American cohort with different underlying liver conditions demonstrating an association between lower tumoral miRNA-26a expression and the postoperative recurrence rate [21] .…”

Section: Rna Studiesmentioning

confidence: 99%

“…Jones et al and von Felden et al investigated the role of miRNAs regarding the recurrence of hepatocellular carcinoma after curative liver resections [20,21] . Jones et al included only a North American cohort with different underlying liver conditions demonstrating an association between lower tumoral miRNA-26a expression and the postoperative recurrence rate [21] . Von Felden et al concluded that there is a significant association between high expression of miRNA-135 and early HCC recurrence [20] .…”

Section: Rna Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Hepatocellular Carcinoma: Systematic Review of Relevant Biomarkers and the Impact on Liver Resections

Bocşe

Ciocan²,

Zaharie³

et al. 2022

ijirms

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the primary cancer of the liver representing the 6th cause of cancer worldwide and the 3rd in terms of deaths per year. Recent advances have offered new treatment options for this disease. New links between biomarkers and patients’ prognosis show a great potential for a more precise and targeted therapy. Method: A systematic review was performed following the guidelines outlined by The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Original articles published in the online database, Pubmed (Medline), Embase and Cochrane from January 2017 to February 2022 were screened after using specific keywords. Results: A total of 1300 studies was obtained by searching through online databases. Following the exclusion criteria, we included 18 studies in the systematic review. Conclusions: Biological markers are playing an important role for the prognosis of HCC. Alfa-fetoprotein (AFP) is still a valid biomarker, that can help stratify the risk for patients with HCC. Meanwhile, the current advancements in the field of miRNAs open new opportunities to analyse the role of miRNAs in HCC. Studies conducted on targeted therapies should also take into consideration the levels of these biomarkers, statistically linked with the prognosis of patients after liver resections.

show abstract

Lower expression of tumor microRNA‐26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment

Abstract: Reduced miR-26a expression is a common phenomenon in HCC arising in North American patients with different underlying liver diseases and may increase recurrence and mortality after surgery.

Cited by 7 publications

References 22 publications

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Hepatocellular Carcinoma: Systematic Review of Relevant Biomarkers and the Impact on Liver Resections

Contact Info

Product

Resources

About